78/100 · Elevated
Manufactured by Lifsa Drugs LLC
Glimepiride Adverse Events: High Seriousness and Diverse Reactions
66,685 FDA adverse event reports analyzed
Last updated: 2026-05-12
GLIMEPIRIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lifsa Drugs LLC. Based on analysis of 66,685 FDA adverse event reports, GLIMEPIRIDE has a safety score of 78 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for GLIMEPIRIDE include BLOOD GLUCOSE INCREASED, NAUSEA, DIARRHOEA, DRUG INEFFECTIVE, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLIMEPIRIDE.
Glimepiride has a safety concern score of 78 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 66,685 adverse event reports for this medication, which is primarily manufactured by Lifsa Drugs Llc.
The most commonly reported adverse events include Blood Glucose Increased, Nausea, Diarrhoea. Of classified reports, 64.4% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The most common adverse reactions include hypoglycemia, weight decrease, and dizziness, indicating a significant risk of hypoglycemia.
A diverse range of reactions, including renal impairment and acute kidney injury, suggests potential organ toxicity. Serious adverse events account for 64.4% of all reports, highlighting the severity of some reactions.
Patients taking Glimepiride should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Glimepiride can cause hypoglycemia, and it is important to monitor blood glucose levels, especially in elderly patients. Drug interactions, particularly with other antidiabetic agents, should be carefully managed. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Glimepiride received a safety concern score of 78/100 (high concern). This is based on a 64.4% serious event ratio across 37,922 classified reports. The score accounts for 66,685 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Male: 18,299, Female: 17,650, Unknown: 61. The most frequently reported age groups are age 70 (946 reports), age 72 (905 reports), age 69 (886 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 37,922 classified reports for GLIMEPIRIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Glimepiride can cause hypoglycemia, and it is important to monitor blood glucose levels, especially in elderly patients. Drug interactions, particularly with other antidiabetic agents, should be carefully managed.
If you are taking Glimepiride, here are important things to know. The most commonly reported side effects include blood glucose increased, nausea, diarrhoea, drug ineffective, fatigue. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor blood glucose levels regularly, especially in elderly patients and those with renal impairment. Be cautious with dose adjustments and avoid abrupt changes to minimize the risk of hypoglycemia. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor Glimepiride for safety, and regulatory actions may be taken based on ongoing data analysis. Healthcare providers should be vigilant in managing patient safety.
The FDA has received approximately 66,685 adverse event reports associated with Glimepiride. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Glimepiride include Blood Glucose Increased, Nausea, Diarrhoea, Drug Ineffective, Fatigue. By volume, the top reported reactions are: Blood Glucose Increased (2,970 reports), Nausea (2,275 reports), Diarrhoea (2,170 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Glimepiride.
Out of 37,922 classified reports, 24,406 (64.4%) were classified as serious and 13,516 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Glimepiride break down by patient sex as follows: Male: 18,299, Female: 17,650, Unknown: 61. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Glimepiride adverse events are: age 70: 946 reports, age 72: 905 reports, age 69: 886 reports, age 68: 865 reports, age 66: 859 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Glimepiride adverse event reports is Lifsa Drugs Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Glimepiride include: Hypoglycaemia, Weight Decreased, Dizziness, Dyspnoea, Vomiting. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Glimepiride to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Glimepiride has a safety concern score of 78 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The most common adverse reactions include hypoglycemia, weight decrease, and dizziness, indicating a significant risk of hypoglycemia.
Key safety signals identified in Glimepiride's adverse event data include: Hypoglycemia is a key safety signal, with 1639 reports, indicating a significant risk.. Renal impairment and acute kidney injury are also notable, with 967 and 1214 reports respectively.. There are multiple reports of cardiovascular events, including myocardial infarction and atrial fibrillation.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Glimepiride can cause hypoglycemia, and it is important to monitor blood glucose levels, especially in elderly patients. Drug interactions, particularly with other antidiabetic agents, should be carefully managed. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Glimepiride.
Monitor blood glucose levels regularly, especially in elderly patients and those with renal impairment. Be cautious with dose adjustments and avoid abrupt changes to minimize the risk of hypoglycemia.
Glimepiride has 66,685 adverse event reports on file with the FDA. A diverse range of reactions, including renal impairment and acute kidney injury, suggests potential organ toxicity. The volume of reports for Glimepiride reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor Glimepiride for safety, and regulatory actions may be taken based on ongoing data analysis. Healthcare providers should be vigilant in managing patient safety. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
The following drugs share commonly reported adverse reactions with GLIMEPIRIDE:
Drugs related to GLIMEPIRIDE based on therapeutic use, drug class, or shared indications: